Hydrazone Cannabinoid Receptor Modulators for Neuropathic Pain
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neuropathic pain and other cannabinoid receptor-mediated disorders lack effective solutions, with existing cannabinoid receptor modulators often causing psychoactive side effects and limited therapeutic benefits.
Innovation Solution
Development of novel hydrazone compounds that selectively modulate CB1 and CB2 cannabinoid receptors, providing therapeutic benefits without psychoactive effects by administering these compounds to treat neuropathic pain and other disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing cannabinoid receptor modulators are used to treat neuropathic pain, then therapeutic benefits are provided, but psychoactive side effects occur
Solution Approach 1:
The patent applies local quality by designing hydrazone compounds with specific molecular structures (Formula I and II) that target CB2 receptors preferentially while minimizing CB1 receptor interaction. The compounds feature specific substituent patterns (R1-R16 groups) that confer selective affinity for CB2 over CB1, thereby providing therapeutic benefits through CB2 activation while avoiding the psychoactive side effects associated with CB1 activation.
Solution Approach 2:
The patent employs parameter changes by systematically varying the chemical structure parameters of the hydrazone compounds (different R groups, substitution patterns, and molecular configurations) to optimize the ratio of CB2 to CB1 receptor binding affinity. By adjusting these molecular parameters, the compounds achieve high CB2 selectivity (CB1/CB2 selectivity ratio > 10), thereby decoupling therapeutic efficacy from psychoactive side effects.
2Object-affected harmful factors
If conventional treatments for neuropathic pain are used, then limited therapeutic benefits are achieved, but no psychoactive effects occur
Solution Approach 1:
The patent uses the hydrazone compounds as intermediaries that selectively activate CB2 receptors to mediate pain relief without activating CB1 receptors. These compounds serve as a bridge between the desired therapeutic outcome (pain relief through cannabinoid receptor activation) and the avoidance of harmful effects (psychoactivity), by specifically targeting CB2 receptors as the intermediary pathway for analgesia.
3Reliability
If CB1 receptor activation is used for pain treatment, then analgesic effects are achieved, but psychoactive side effects and limited therapeutic benefits occur
Solution Approach 1:
The patent applies segmentation by separating the analgesic function from the psychoactive function through selective CB2 receptor targeting. Instead of using non-selective cannabinoid agonists that activate both CB1 and CB2 receptors, the hydrazone compounds are designed to segment their pharmacological activity, activating only CB2 receptors to provide pain relief while leaving CB1-mediated psychoactive pathways untouched.
Data Source
AI summary
Hydrazone compounds which modulate cannabinoid receptors are presented. Pharmaceutical compositions containing these compounds, methods of using these compounds as modulators of cannabinoid receptors and processes for synthesizing these compounds are also described herein.